Iovance Biotherapeutics shares are trading higher after the company announced the FDA lifted a partial clinical hold on the registrational IOV-LUN-202 trial investigating LN-145 TIL cell therapy in non-small cell lung cancer.
Portfolio Pulse from Benzinga Newsdesk
Iovance Biotherapeutics' stock is trading higher following the announcement that the FDA has lifted a partial clinical hold on the IOV-LUN-202 trial, which is investigating LN-145 TIL cell therapy for non-small cell lung cancer.
March 04, 2024 | 1:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Iovance Biotherapeutics' shares are trading higher after the FDA lifted a partial clinical hold on their IOV-LUN-202 trial for LN-145 TIL cell therapy in non-small cell lung cancer.
The lifting of the FDA's partial clinical hold on the IOV-LUN-202 trial is a significant positive development for Iovance Biotherapeutics. It allows the company to continue its research on LN-145 TIL cell therapy for non-small cell lung cancer, potentially leading to breakthrough treatments. This regulatory progress is likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100